TRANSFORMING CLINICAL CARE: IMPACT OF LEUKAEMIA FOUNDATION’S RESEARCH FUNDING INTO BLOOD CANCER
With
Bill Stavreski, Head of Research
Leukaemia Foundation, Australia
RESEARCH IMPACT
Filmed in Melbourne | May 2025
Released to coincide with World Blood Cancer Day 2025
The Leukaemia Foundation is committed to funding research innovations that drive advancements in new diagnostics, treatments and novel therapies, supporting the careers of promising scientists and clinicians and giving Australians access to global clinical trials.
The Leukaemia Foundation state there are over 120 different types of blood cancer and all of which the Foundation provides support to people.
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
The Foundation primarily relies on the generosity of public donations, with no government funding. This funding has led to significant advancements in clinical practice, including a groundbreaking diagnostic test now available across Australia, significantly easing the financial burden on patients.
One notable achievement includes the first successful growth of leukaemic cells in a dish, facilitating advancements in treatment testing. Additionally, the Foundation established a pioneering genomic screening program for patients with hard-to-treat blood cancers, significantly improving the chances of finding effective treatments.
Through this work, the Foundation underscores that research is centred on people, aiming to transform lives and support families affected by blood cancer.
Source: Adapted from the Leukaemia Foundation website and transcript
-
Anaemia guidelines updated after 50 years
Professor Sant-Rayn Pasricha is the Acting Deputy Director at the Walter Eliza Hall Institute of Medical Research in Melbourne, Australia. He is also a clinical haematologist at the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. From a young age, Prof Pasricha dreamed of becoming a doctor and found joy in learning about the human body and how to care for patients. After completing medical school, he developed a passion for working in low and middle-income countries, which led him to spend time working in East Timor, India, and Central Australia with First Nations communities.
-
Earlier identification and early intervention for children who are deaf or hard of hearing
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities. He has held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
